The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the effect of an investigational drug on bone loss
in men with prostate cancer who are receiving Androgen Deprivation Therapy (ADT).
In order to participate, male patients 18 years and older must be veterans from participating
Veterans Administration Medical Centers that are receiving ADT for prostate cancer and have
established osteoporosis.